Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives (Q37004639)

17 August 2017

1 reference

title

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives (English)

1 reference

17 August 2017

3

Yung-Jue Bang

1 reference

17 August 2017

2

Sae-Won Han

1 reference

17 August 2017

1

Tae-You Kim

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

821-836

1 reference

Untangling the ErbB signalling network

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

STAT proteins: From normal control of cellular events to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Her2-targeted therapies in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Tobacco Smoke-induced Lung Cell Proliferation Mediated by Tumor Necrosis Factor α-converting Enzyme and Amphiregulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

Mutations of epidermal growth factor receptor andK-rasgenes in adenosquamous carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737159.7.6.821

21 January 2018

Identifiers

DOI

10.1586/14737159.7.6.821

1 reference

release_ih63cubd45beboap7mh7utp534

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ih63cubd45beboap7mh7utp534

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference